Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Lymphoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 174 articles:
HTML format



Single Articles


    June 2021
  1. OVLISEN AK, Jakobsen LH, Eloranta S, Kragholm KH, et al
    Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study.
    J Clin Oncol. 2021 Jun 25:JCO2100357. doi: 10.1200/JCO.21.00357.
    PubMed     Abstract available


  2. MOSKOWITZ AJ, Shah G, Schoder H, Ganesan N, et al
    Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jun 25:JCO2101056. doi: 10.1200/JCO.21.01056.
    PubMed     Abstract available


  3. DEMEESTERE I, Racape J, Dechene J, Dupuis J, et al
    Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).
    J Clin Oncol. 2021 Jun 22:JCO2100068. doi: 10.1200/JCO.21.00068.
    PubMed     Abstract available


    April 2021
  4. ALIG S, Macaulay CW, Kurtz DM, Duhrsen U, et al
    Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2002573. doi: 10.1200/JCO.20.02573.
    PubMed     Abstract available


  5. KUMAR A, Casulo C, Advani RH, Budde E, et al
    Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2100108. doi: 10.1200/JCO.21.00108.
    PubMed     Abstract available


  6. METZGER ML, Link MP, Billett AL, Flerlage J, et al
    Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
    J Clin Oncol. 2021 Apr 7:JCO2003286. doi: 10.1200/JCO.20.03286.
    PubMed     Abstract available


    March 2021
  7. HUTCHINGS M, Morschhauser F, Iacoboni G, Carlo-Stella C, et al
    Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    J Clin Oncol. 2021 Mar 19:JCO2003175. doi: 10.1200/JCO.20.03175.
    PubMed     Abstract available


  8. FOWLER NH, Samaniego F, Jurczak W, Ghosh N, et al
    Umbralisib, a Dual PI3Kdelta/CK1epsilon Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2021 Mar 8:JCO2003433. doi: 10.1200/JCO.20.03433.
    PubMed     Abstract available


    February 2021
  9. OEFFINGER KC, Stratton KL, Hudson MM, Leisenring WM, et al
    Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2021 Feb 25:JCO2001186. doi: 10.1200/JCO.20.01186.
    PubMed     Abstract available


  10. NOWAKOWSKI GS, Chiappella A, Gascoyne RD, Scott DW, et al
    ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2021 Feb 23:JCO2001366. doi: 10.1200/JCO.20.01366.
    PubMed     Abstract available


  11. MERLI F, Luminari S, Tucci A, Arcari A, et al
    Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi.
    J Clin Oncol. 2021 Feb 12:JCO2002465. doi: 10.1200/JCO.20.02465.
    PubMed     Abstract available


  12. NOWAKOWSKI GS, Hong F, Scott DW, Macon WR, et al
    Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
    J Clin Oncol. 2021 Feb 8:JCO2001375. doi: 10.1200/JCO.20.01375.
    PubMed     Abstract available


  13. KHURANA A, Mwangi R, Nowakowski GS, Habermann TM, et al
    Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
    J Clin Oncol. 2021 Feb 2:JCO2001935. doi: 10.1200/JCO.20.01935.
    PubMed     Abstract available


    January 2021
  14. VASILEIOU S, Lulla PD, Tzannou I, Watanabe A, et al
    T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
    J Clin Oncol. 2021 Jan 28:JCO2002224. doi: 10.1200/JCO.20.02224.
    PubMed     Abstract available


  15. OLSZEWSKI AJ, Jakobsen LH, Collins GP, Cwynarski K, et al
    Burkitt Lymphoma International Prognostic Index.
    J Clin Oncol. 2021 Jan 27:JCO2003288. doi: 10.1200/JCO.20.03288.
    PubMed     Abstract available


  16. OBERIC L, Peyrade F, Puyade M, Bonnet C, et al
    Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
    J Clin Oncol. 2021 Jan 14:JCO2002666. doi: 10.1200/JCO.20.02666.
    PubMed     Abstract available


  17. KOMANDURI KV
    Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jan 12:JCO2001749. doi: 10.1200/JCO.20.01749.
    PubMed    


  18. SHAH NN, Hamadani M
    Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?
    J Clin Oncol. 2021 Jan 12:JCO2001447. doi: 10.1200/JCO.20.01447.
    PubMed    


  19. ANSELL SM
    Checkpoint BLOCKade in Lymphoma.
    J Clin Oncol. 2021 Jan 12:JCO2001522. doi: 10.1200/JCO.20.01522.
    PubMed    


  20. LUSSANA F, Gritti G, Rambaldi A
    Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    J Clin Oncol. 2021 Jan 12:JCO2001564. doi: 10.1200/JCO.20.01564.
    PubMed    


  21. ALENCAR AJ, Moskowitz CH
    Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jan 12:JCO2001751. doi: 10.1200/JCO.20.01751.
    PubMed    


    December 2020
  22. HAWKES EA, Opat S, Hertzberg M
    Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL.
    J Clin Oncol. 2020;38:4221-4222.
    PubMed    


  23. PERSKY DO, Smith SM, LeBlanc ML, Friedberg JW, et al
    Reply to E. Hawkes et al.
    J Clin Oncol. 2020;38:4222-4223.
    PubMed    


  24. CRUMP M
    Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma?
    J Clin Oncol. 2020 Dec 4:JCO2002905. doi: 10.1200/JCO.20.02905.
    PubMed    


    November 2020
  25. CAPPELL KM, Sherry RM, Yang JC, Goff SL, et al
    Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    J Clin Oncol. 2020;38:3805-3815.
    PubMed     Abstract available


  26. ROSCHEWSKI M, Dunleavy K, Wilson WH
    Reply to M. Hertzberg et al.
    J Clin Oncol. 2020;38:3723-3724.
    PubMed    


    October 2020
  27. CROMBIE JL, Armand P
    Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm.
    J Clin Oncol. 2020;38:3565-3574.
    PubMed    


  28. JAIN P, Dreyling M, Seymour JF, Wang M, et al
    High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.
    J Clin Oncol. 2020 Oct 19:JCO2002287. doi: 10.1200/JCO.20.02287.
    PubMed    


  29. BROCKELMANN PJ, Muller H, Guhl T, Behringer K, et al
    Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy.
    J Clin Oncol. 2020 Oct 15:JCO2000947. doi: 10.1200/JCO.20.00947.
    PubMed     Abstract available


  30. O'BRIEN MM
    Defining the Optimal Treatment of First Relapse of Pediatric Relapsed Anaplastic Large-Cell Lymphoma: Clinical Trial Challenges for Rare Diagnoses.
    J Clin Oncol. 2020 Oct 15:JCO2002285. doi: 10.1200/JCO.20.02285.
    PubMed    


  31. EVENS AM, Parsons SK
    Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality.
    J Clin Oncol. 2020 Oct 8:JCO2002668. doi: 10.1200/JCO.20.02668.
    PubMed    


    September 2020
  32. JACOBSON CA, Hunter BD, Redd R, Rodig SJ, et al
    Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
    J Clin Oncol. 2020;38:3095-3106.
    PubMed     Abstract available


  33. GALLAMINI A, Rossi A, Patti C, Picardi M, et al
    Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial.
    J Clin Oncol. 2020 Sep 18:JCO2000935. doi: 10.1200/JCO.20.00935.
    PubMed     Abstract available


  34. DORES GM, Curtis RE, Dalal NH, Linet MS, et al
    Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.
    J Clin Oncol. 2020 Sep 18:JCO2000264. doi: 10.1200/JCO.20.00264.
    PubMed     Abstract available


  35. BROCKELMANN PJ, Borchmann S, Borchmann P, Engert A, et al
    Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche.
    J Clin Oncol. 2020 Sep 18:JCO2002351. doi: 10.1200/JCO.20.02351.
    PubMed    


  36. HERTZBERG M, Joske DJL, Gandhi MK
    DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
    J Clin Oncol. 2020 Sep 15:JCO2001850. doi: 10.1200/JCO.20.01850.
    PubMed    


    August 2020
  37. JAFFE ES, Feldman AL, Gaulard P, Miranda RN, et al
    Reply to M. Romero et al.
    J Clin Oncol. 2020;38:2819-2820.
    PubMed    


    July 2020
  38. KNORR F, Brugieres L, Pillon M, Zimmermann M, et al
    Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
    J Clin Oncol. 2020 Jul 30:JCO2000157. doi: 10.1200/JCO.20.00157.
    PubMed     Abstract available


  39. LUGTENBURG PJ, de Nully Brown P, van der Holt B, D'Amore FA, et al
    Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
    J Clin Oncol. 2020 Jul 30:JCO1903418. doi: 10.1200/JCO.19.03418.
    PubMed     Abstract available


  40. RAMOS CA, Grover NS, Beaven AW, Lulla PD, et al
    Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
    J Clin Oncol. 2020 Jul 23:JCO2001342. doi: 10.1200/JCO.20.01342.
    PubMed     Abstract available


  41. GHESQUIERES H, Salles G
    Early Off-Study Experience of Chimeric Antigen Receptor T Cells in Aggressive Lymphoma: Closer to a Real-World Setting.
    J Clin Oncol. 2020 Jul 15:JCO2001134. doi: 10.1200/JCO.20.01134.
    PubMed    


  42. PERSKY DO, Li H, Stephens DM, Park SI, et al
    Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
    J Clin Oncol. 2020 Jul 13:JCO2000999. doi: 10.1200/JCO.20.00999.
    PubMed     Abstract available


  43. PARSONS SK
    Longitudinal Assessment of Health-Related Quality of Life Among Survivors of Hodgkin Lymphoma: It Is About Time!
    J Clin Oncol. 2020 Jul 10:JCO2001585. doi: 10.1200/JCO.20.01585.
    PubMed    


    June 2020
  44. KREISSL S, Muller H, Goergen H, Meissner J, et al
    Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group.
    J Clin Oncol. 2020 Jun 23:JCO1903160. doi: 10.1200/JCO.19.03160.
    PubMed     Abstract available


  45. FROSCH ZAK, Landsburg DJ
    Molecular Risk Stratification in Aggressive B-Cell Lymphomas.
    J Clin Oncol. 2020;38:2014-2017.
    PubMed    


  46. HAYASHI RJ, Winter SS, Dunsmore KP, Devidas M, et al
    Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    J Clin Oncol. 2020 Jun 17:JCO2000531. doi: 10.1200/JCO.20.00531.
    PubMed     Abstract available


  47. ROMERO M, Melo A, Bedoya N, de la Hoz J, et al
    Should Flow Cytometry Be Considered a First Line of Study in the Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma?
    J Clin Oncol. 2020 Jun 17:JCO2000712. doi: 10.1200/JCO.20.00712.
    PubMed    


    May 2020
  48. ROSCHEWSKI M, Dunleavy K, Abramson JS, Powell BL, et al
    Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
    J Clin Oncol. 2020 May 26:JCO2000303. doi: 10.1200/JCO.20.00303.
    PubMed     Abstract available


  49. NASTOUPIL LJ, Jain MD, Feng L, Spiegel JY, et al
    Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
    J Clin Oncol. 2020 May 13:JCO1902104. doi: 10.1200/JCO.19.02104.
    PubMed     Abstract available


  50. VAN BESIEN KW, Orfali N
    Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come.
    J Clin Oncol. 2020;38:1501-1504.
    PubMed    


    April 2020
  51. FUCHS M, Goergen H, Kobe C, Borchmann P, et al
    Reply to H.J.A. Adams et al.
    J Clin Oncol. 2020;38:1116-1117.
    PubMed    


    March 2020
  52. MORTON LM
    Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors.
    J Clin Oncol. 2020 Mar 31:JCO2000361. doi: 10.1200/JCO.20.00361.
    PubMed    


    February 2020
  53. SHREE T, Li Q, Glaser SL, Brunson A, et al
    Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2020 Feb 21:JCO1901937. doi: 10.1200/JCO.19.01937.
    PubMed     Abstract available


  54. TOBIN JWD, Keane C, Gunawardana J, Gandhi MK, et al
    Reply to M. Sorigue.
    J Clin Oncol. 2020;38:648-649.
    PubMed    


  55. JAFFE ES, Ashar BS, Clemens MW, Feldman AL, et al
    Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
    J Clin Oncol. 2020 Feb 11:JCO1902778. doi: 10.1200/JCO.19.02778.
    PubMed     Abstract available


  56. BACHY E, Salles G
    Reply to S. Fuji.
    J Clin Oncol. 2020;38:523.
    PubMed    


  57. FUJI S
    Answer to Simulation Analysis of Cost-Effectiveness in 2012 Has Finally Come in 2019.
    J Clin Oncol. 2020;38:522.
    PubMed    


  58. MANZ CR, Porter DL, Bekelman JE
    Innovation and Access at the Mercy of Payment Policy: The Future of Chimeric Antigen Receptor Therapies.
    J Clin Oncol. 2020;38:384-387.
    PubMed    


  59. FATOBENE G, Rocha V, St Martin A, Hamadani M, et al
    Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.
    J Clin Oncol. 2020 Feb 7:JCO1902408. doi: 10.1200/JCO.19.02408.
    PubMed     Abstract available


    January 2020
  60. ADAMS HJA, Kwee TC
    Inability of Fluorodeoxyglucose Positron Emission Tomography to Detect Viable Hodgkin Lymphoma During and After Treatment.
    J Clin Oncol. 2020 Jan 30:JCO1902780. doi: 10.1200/JCO.19.02780.
    PubMed    


  61. BARTLETT NL
    Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle.
    J Clin Oncol. 2020 Jan 10:JCO1902816. doi: 10.1200/JCO.19.02816.
    PubMed     Abstract available


  62. KHODADOUST MS, Rook AH, Porcu P, Foss F, et al
    Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome: A Multicenter Phase II Study.
    J Clin Oncol. 2020;38:20-28.
    PubMed     Abstract available


    December 2019
  63. SORIGUE M
    Immune Infiltration and the Potential for a Biology-Guided Approach to Follicular Lymphoma.
    J Clin Oncol. 2019 Dec 9:JCO1902398. doi: 10.1200/JCO.19.02398.
    PubMed    


  64. KLUIN-NELEMANS HC, Hoster E, Hermine O, Walewski J, et al
    Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    J Clin Oncol. 2019 Dec 5:JCO1901294. doi: 10.1200/JCO.19.01294.
    PubMed     Abstract available


    November 2019
  65. SHINGLETON JR, Dave SS
    Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Nov 26:JCO1902587. doi: 10.1200/JCO.19.02587.
    PubMed    


  66. SEHN LH, Herrera AF, Flowers CR, Kamdar MK, et al
    Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Nov 6:JCO1900172. doi: 10.1200/JCO.19.00172.
    PubMed     Abstract available


    October 2019
  67. EICHENAUER DA, Plutschow A, Fuchs M, Sasse S, et al
    Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
    J Clin Oncol. 2019 Oct 18:JCO1900986. doi: 10.1200/JCO.19.00986.
    PubMed     Abstract available


  68. BORCHMANN S, Cirillo M, Goergen H, Meder L, et al
    Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma.
    J Clin Oncol. 2019 Oct 17:JCO1900985. doi: 10.1200/JCO.19.00985.
    PubMed     Abstract available


  69. ARMAND P, Rodig S, Melnichenko V, Thieblemont C, et al
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Oct 14:JCO1901389. doi: 10.1200/JCO.19.01389.
    PubMed     Abstract available


    September 2019
  70. KOBE C, Goergen H, Fuchs M, Muller H, et al
    Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2019 Sep 30:JCO1901761. doi: 10.1200/JCO.19.01761.
    PubMed    


  71. ADAMS HJA, Kwee TC
    Only a Small Proportion of Patients With Early-Stage Hodgkin Lymphoma May Potentially Benefit From Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment Escalation.
    J Clin Oncol. 2019 Sep 30:JCO1901491. doi: 10.1200/JCO.19.01491.
    PubMed    


  72. KAHN JM, Kelly KM, Pei Q, Bush R, et al
    Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study.
    J Clin Oncol. 2019 Sep 20:JCO1900812. doi: 10.1200/JCO.19.00812.
    PubMed     Abstract available


  73. FUCHS M, Goergen H, Kobe C, Kuhnert G, et al
    Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
    J Clin Oncol. 2019 Sep 10:JCO1900964. doi: 10.1200/JCO.19.00964.
    PubMed     Abstract available


  74. ROSENWALD A, Bens S, Advani R, Barrans S, et al
    Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
    J Clin Oncol. 2019 Sep 9:JCO1900743. doi: 10.1200/JCO.19.00743.
    PubMed     Abstract available


    August 2019
  75. TOBIN JWD, Keane C, Gunawardana J, Mollee P, et al
    Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
    J Clin Oncol. 2019 Aug 28:JCO1802365. doi: 10.1200/JCO.18.02365.
    PubMed     Abstract available


  76. ZINZANI PL, Santoro A, Gritti G, Brice P, et al
    Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
    J Clin Oncol. 2019 Aug 9:JCO1901492. doi: 10.1200/JCO.19.01492.
    PubMed     Abstract available


    July 2019
  77. BACHY E, Seymour JF, Feugier P, Offner F, et al
    Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
    J Clin Oncol. 2019 Jul 24:JCO1901073. doi: 10.1200/JCO.19.01073.
    PubMed     Abstract available


  78. EHRHARDT MJ, Chen Y, Sandlund JT, Bluhm EC, et al
    Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 8:JCO1900525. doi: 10.1200/JCO.19.00525.
    PubMed     Abstract available


  79. OEFFINGER KC, Ford JS, Moskowitz CS, Chou JF, et al
    Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1900547. doi: 10.1200/JCO.19.00547.
    PubMed     Abstract available


    June 2019
  80. WANG Y, Farooq U, Link BK, Larson MC, et al
    Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
    J Clin Oncol. 2019 Jun 6:JCO1900014. doi: 10.1200/JCO.19.00014.
    PubMed     Abstract available


  81. LIN JK, Muffly LS, Spinner MA, Barnes JI, et al
    Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Jun 3:JCO1802079. doi: 10.1200/JCO.18.02079.
    PubMed     Abstract available


    May 2019
  82. RAMCHANDREN R, Domingo-Domenech E, Rueda A, Trneny M, et al
    Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
    J Clin Oncol. 2019 May 21:JCO1900315. doi: 10.1200/JCO.19.00315.
    PubMed     Abstract available


  83. BARRINGTON SF, Phillips EH, Counsell N, Hancock B, et al
    Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.
    J Clin Oncol. 2019 May 21:JCO1801799. doi: 10.1200/JCO.18.01799.
    PubMed     Abstract available


    April 2019
  84. NIE J, Wang C, Liu Y, Yang Q, et al
    Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    J Clin Oncol. 2019 Apr 30:JCO1802151. doi: 10.1200/JCO.18.02151.
    PubMed     Abstract available


  85. SIKIC BI, Lakhani N, Patnaik A, Shah SA, et al
    First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
    J Clin Oncol. 2019;37:946-953.
    PubMed     Abstract available


  86. LEONARD JP
    De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Apr 2:JCO1900445. doi: 10.1200/JCO.19.00445.
    PubMed    


  87. BARTLETT NL, Wilson WH, Jung SH, Hsi ED, et al
    Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
    J Clin Oncol. 2019 Apr 2:JCO1801994. doi: 10.1200/JCO.18.01994.
    PubMed     Abstract available


  88. HUNTINGTON SF, von Keudell G, Davidoff AJ, Gross CP, et al
    Reply to H.J.A. Adams et al.
    J Clin Oncol. 2019;37:853-854.
    PubMed    


    March 2019
  89. YOUNES A, Sehn LH, Johnson P, Zinzani PL, et al
    Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Mar 22:JCO1802403. doi: 10.1200/JCO.18.02403.
    PubMed     Abstract available


  90. BARR PM
    Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab.
    J Clin Oncol. 2019 Mar 22:JCO1900419. doi: 10.1200/JCO.19.00419.
    PubMed    


  91. LEONARD JP, Trneny M, Izutsu K, Fowler NH, et al
    AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2019 Mar 21:JCO1900010. doi: 10.1200/JCO.19.00010.
    PubMed     Abstract available


  92. SHAW AT, Solomon BJ, Besse B, Bauer TM, et al
    ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Mar 20:JCO1802236. doi: 10.1200/JCO.18.02236.
    PubMed     Abstract available


  93. KURTZ DM, Scherer F, Jin MC, Soo J, et al
    Reply to J. Wang et al.
    J Clin Oncol. 2019;37:755-757.
    PubMed    


  94. LOCKMER S, Ostenstad B, Hagberg H, Holte H, et al
    Reply to M. Sorigue et al.
    J Clin Oncol. 2019;37:759-760.
    PubMed    


    February 2019
  95. FLINN IW, van der Jagt R, Kahl B, Wood P, et al
    First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    J Clin Oncol. 2019 Feb 27:JCO1800605. doi: 10.1200/JCO.18.00605.
    PubMed     Abstract available


  96. FRUMAN DA
    Targeting PI3K-Gamma in Non-Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 27:JCO1900215. doi: 10.1200/JCO.19.00215.
    PubMed    


  97. HOUILLIER C, Taillandier L, Dureau S, Lamy T, et al
    Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
    J Clin Oncol. 2019 Feb 20:JCO1800306. doi: 10.1200/JCO.18.00306.
    PubMed     Abstract available


  98. SHI Q, Flowers CR
    Reply to H.J.A. Adams et al.
    J Clin Oncol. 2019;37:526-527.
    PubMed    


  99. WANG J, Dong R, Li K
    Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Feb 12:JCO1801385. doi: 10.1200/JCO.18.01385.
    PubMed    


  100. FLINN IW, Miller CB, Ardeshna KM, Tetreault S, et al
    DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 11:JCO1800915. doi: 10.1200/JCO.18.00915.
    PubMed     Abstract available


  101. ADAMS HJA, Kwee TC
    A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 11:JCO1801830. doi: 10.1200/JCO.18.01830.
    PubMed    


  102. SORIGUE M, Sancho JM
    Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?
    J Clin Oncol. 2019 Feb 8:JCO1801761. doi: 10.1200/JCO.18.01761.
    PubMed    


  103. BICCLER JL, Glimelius I, Eloranta S, Smeland KB, et al
    Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.
    J Clin Oncol. 2019 Feb 6:JCO1801652. doi: 10.1200/JCO.18.01652.
    PubMed     Abstract available


  104. O'CONNOR OA, Ozcan M, Jacobsen ED, Roncero JM, et al
    Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2019 Feb 1:JCO1800899. doi: 10.1200/JCO.18.00899.
    PubMed     Abstract available


    January 2019
  105. MACMANUS M, Fisher R, McClure B, Seymour JF, et al
    Reply to M. Sorigue et al.
    J Clin Oncol. 2019;37:257-258.
    PubMed    


  106. COOK LB, Fuji S, Hermine O, Bazarbachi A, et al
    Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
    J Clin Oncol. 2019 Jan 18:JCO1800501. doi: 10.1200/JCO.18.00501.
    PubMed     Abstract available


  107. GILLIGAN T
    Personalizing Medicine.
    J Clin Oncol. 2019;37:165-166.
    PubMed    


  108. ANSELL SM, Minnema MC, Johnson P, Timmerman JM, et al
    Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    J Clin Oncol. 2019 Jan 8:JCO1800766. doi: 10.1200/JCO.18.00766.
    PubMed     Abstract available


  109. GERSON JN, Handorf E, Villa D, Gerrie AS, et al
    Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
    J Clin Oncol. 2019 Jan 7:JCO1800690. doi: 10.1200/JCO.18.00690.
    PubMed     Abstract available


    December 2018
  110. ADAMS HJA, Kwee TC
    Standardized Definition of Progression-Free Survival in Diffuse Large B-Cell Lymphoma Is Urgently Needed.
    J Clin Oncol. 2018 Dec 28:JCO1801134. doi: 10.1200/JCO.18.01134.
    PubMed    


  111. JACOBSON CA
    CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2018 Dec 13:JCO1801457. doi: 10.1200/JCO.18.01457.
    PubMed     Abstract available


  112. SHA C, Barrans S, Cucco F, Bentley MA, et al
    Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
    J Clin Oncol. 2018 Dec 3:JCO1801314. doi: 10.1200/JCO.18.01314.
    PubMed     Abstract available


  113. CHAN WC
    Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801910. doi: 10.1200/JCO.18.01910.
    PubMed    


  114. ENNISHI D, Jiang A, Boyle M, Collinge B, et al
    Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801583. doi: 10.1200/JCO.18.01583.
    PubMed     Abstract available


    November 2018
  115. SARKOZY C, Maurer MJ, Link BK, Ghesquieres H, et al
    Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    J Clin Oncol. 2018 Nov 27:JCO1800400. doi: 10.1200/JCO.18.00400.
    PubMed     Abstract available


  116. SORIGUE M, Sancho JM
    Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography.
    J Clin Oncol. 2018 Nov 26:JCO1800854. doi: 10.1200/JCO.18.00854.
    PubMed    


    October 2018
  117. DAVIDS MS, von Keudell G, Portell CA, Cohen JB, et al
    Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
    J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359.
    PubMed    


  118. ALDERUCCIO JP, Zhao W, Desai A, Gallastegui N, et al
    Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.
    J Clin Oncol. 2018 Oct 12:JCO1800138. doi: 10.1200/JCO.18.00138.
    PubMed     Abstract available


  119. LOCKMER S, Ostenstad B, Hagberg H, Holte H, et al
    Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
    J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262.
    PubMed     Abstract available


  120. HUNTINGTON SF, von Keudell G, Davidoff AJ, Gross CP, et al
    Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.
    J Clin Oncol. 2018 Oct 4:JCO1800122. doi: 10.1200/JCO.18.00122.
    PubMed     Abstract available


    September 2018
  121. GISSELBRECHT C
    Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study?
    J Clin Oncol. 2018 Sep 17:JCO1800498. doi: 10.1200/JCO.18.00498.
    PubMed    


  122. ADAMS HJA, Kwee TC
    Unproven Clinical Value of Interim FDG-PET in Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 17:JCO1800323. doi: 10.1200/JCO.18.00323.
    PubMed    


  123. EVENS AM, Advani RH, Helenowski IB, Fanale M, et al
    Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 4:JCO2018790139. doi: 10.1200/JCO.2018.79.0139.
    PubMed     Abstract available


    August 2018
  124. YANG JC, Yahalom J
    Early-Stage Follicular Lymphoma: What Is the Preferred Treatment Strategy?
    J Clin Oncol. 2018 Aug 28:JCO2018793075. doi: 10.1200/JCO.2018.79.3075.
    PubMed    


  125. KURTZ DM, Scherer F, Jin MC, Soo J, et al
    Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Aug 20:JCO2018785246. doi: 10.1200/JCO.2018.78.5246.
    PubMed     Abstract available


    July 2018
  126. WEIBULL CE, Johansson ALV, Eloranta S, Smedby KE, et al
    Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.
    J Clin Oncol. 2018 Jul 25:JCO2018783514. doi: 10.1200/JCO.2018.78.3514.
    PubMed     Abstract available


  127. SASSE S, Goergen H, Plutschow A, Boll B, et al
    Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
    J Clin Oncol. 2018 Jul 10:JCO2018787192. doi: 10.1200/JCO.2018.78.7192.
    PubMed     Abstract available


  128. SHI Q, Schmitz N, Ou FS, Dixon JG, et al
    Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    J Clin Oncol. 2018 Jul 5:JCO2018779124. doi: 10.1200/JCO.2018.77.9124.
    PubMed     Abstract available


  129. MACMANUS M, Fisher R, Roos D, O'Brien P, et al
    Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
    J Clin Oncol. 2018 Jul 5:JCO2018779892. doi: 10.1200/JCO.2018.77.9892.
    PubMed     Abstract available


    June 2018
  130. FRIEDBERG JW
    Progress in Advanced-Stage Follicular Lymphoma.
    J Clin Oncol. 2018 Jun 1:JCO2018793083. doi: 10.1200/JCO.2018.79.3083.
    PubMed    


  131. HIDDEMANN W, Barbui AM, Canales MA, Cannell PK, et al
    Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    J Clin Oncol. 2018 Jun 1:JCO2017768960. doi: 10.1200/JCO.2017.76.8960.
    PubMed     Abstract available


    May 2018
  132. GOPAL AK, Schuster SJ, Fowler NH, Trotman J, et al
    Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
    J Clin Oncol. 2018 May 31:JCO2017768853. doi: 10.1200/JCO.2017.76.8853.
    PubMed     Abstract available


  133. MESGUICH C, Bouabdallah K, Milpied N, Hindie E, et al
    Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018786780. doi: 10.1200/JCO.2018.78.6780.
    PubMed    


  134. ADAMS HJA, Kwee TC
    Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018782524. doi: 10.1200/JCO.2018.78.2524.
    PubMed    


  135. MERRYMAN RW, LaCasce AS
    Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.
    J Clin Oncol. 2018 May 22:JCO2018789362. doi: 10.1200/JCO.2018.78.9362.
    PubMed    


  136. LETAI A
    Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2018 May 22:JCO2018782763. doi: 10.1200/JCO.2018.78.2763.
    PubMed    


  137. CAMIDGE DR, Kim DW, Tiseo M, Langer CJ, et al
    Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841.
    PubMed     Abstract available


    April 2018
  138. MAURER MJ, Ghesquieres H, Link BK, Jais JP, et al
    Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
    J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198.
    PubMed     Abstract available


    March 2018
  139. CHESON BD, Chua N, Mayer J, Dueck G, et al
    Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    J Clin Oncol. 2018 Mar 27:JCO2017763656. doi: 10.1200/JCO.2017.76.3656.
    PubMed     Abstract available


  140. ARMAND P, Engert A, Younes A, Fanale M, et al
    Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    J Clin Oncol. 2018 Mar 27:JCO2017760793. doi: 10.1200/JCO.2017.76.0793.
    PubMed     Abstract available


    February 2018
  141. ROEMER MGM, Redd RA, Cader FZ, Pak CJ, et al
    Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    J Clin Oncol. 2018 Feb 2:JCO2017773994. doi: 10.1200/JCO.2017.77.3994.
    PubMed     Abstract available


    January 2018
  142. GALLAMINI A, Tarella C, Viviani S, Rossi A, et al
    Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607
    J Clin Oncol. 2018 Jan 23:JCO2017752543. doi: 10.1200/JCO.2017.75.2543.
    PubMed     Abstract available


  143. SHADMAN M, Li H, Rimsza L, Leonard JP, et al
    Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
    J Clin Oncol. 2018 Jan 22:JCO2017745083. doi: 10.1200/JCO.2017.74.5083.
    PubMed     Abstract available


  144. BOLLARD CM, Tripic T, Cruz CR, Dotti G, et al
    Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
    J Clin Oncol. 2018 Jan 9:JCO2017743179. doi: 10.1200/JCO.2017.74.3179.
    PubMed     Abstract available


    November 2017
  145. LUMINARI S, Ferrari A, Manni M, Dondi A, et al
    Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    J Clin Oncol. 2017 Nov 2:JCO2017741652. doi: 10.1200/JCO.2017.74.1652.
    PubMed     Abstract available


    October 2017
  146. MAURER MJ, Ellin F, Srour L, Jerkeman M, et al
    International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2017 Oct 26:JCO2017738195. doi: 10.1200/JCO.2017.73.8195.
    PubMed     Abstract available


  147. DREYLING M, Santoro A, Mollica L, Leppa S, et al
    Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2017 Oct 4:JCO2017754648. doi: 10.1200/JCO.2017.75.4648.
    PubMed     Abstract available


    September 2017
  148. HERRERA AF, Armand P
    Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
    J Clin Oncol. 2017 Sep 21:JCO2017745281. doi: 10.1200/JCO.2017.74.5281.
    PubMed     Abstract available


  149. SALZ T, Zabor EC, de Nully Brown P, Dalton SO, et al
    Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2017 Sep 18:JCO2017724211. doi: 10.1200/JCO.2017.72.4211.
    PubMed     Abstract available


  150. CHAN FC, Mottok A, Gerrie AS, Power M, et al
    Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.
    J Clin Oncol. 2017 Sep 12:JCO2017727925. doi: 10.1200/JCO.2017.72.7925.
    PubMed     Abstract available


  151. LEONARD JP, Kolibaba KS, Reeves JA, Tulpule A, et al
    Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Sep 1:JCO2017732784. doi: 10.1200/JCO.2017.73.2784.
    PubMed     Abstract available


    August 2017
  152. MARTINEZ C, Gayoso J, Canals C, Finel H, et al
    Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and
    J Clin Oncol. 2017 Aug 28:JCO2017726869. doi: 10.1200/JCO.2017.72.6869.
    PubMed     Abstract available


  153. VITOLO U, Trneny M, Belada D, Burke JM, et al
    Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Aug 10:JCO2017733402. doi: 10.1200/JCO.2017.73.3402.
    PubMed     Abstract available


  154. MOSSE YP, Voss SD, Lim MS, Rolland D, et al
    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    J Clin Oncol. 2017 Aug 8:JCO2017734830. doi: 10.1200/JCO.2017.73.4830.
    PubMed     Abstract available


    July 2017
  155. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    PubMed     Abstract available


  156. VARGO JA, Ling DC, Beriwal S
    Treatment of Early-Stage Hodgkin Lymphoma: Are We Just Shifting Morbidities?
    J Clin Oncol. 2017 Jul 6:JCO2017733568. doi: 10.1200/JCO.2017.73.3568.
    PubMed    


  157. HINDIE E, Mesguich C, Zanotti-Fregonara P
    On the Role of Interim Fluorine-18-Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017738369. doi: 10.1200/JCO.2017.73.8369.
    PubMed    


  158. ADAMS HJA, Kwee TC
    Interim Fluorodeoxyglucose Positron Emission Tomography-Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017733816. doi: 10.1200/JCO.2017.73.3816.
    PubMed    


    June 2017
  159. LEONARD JP, Martin P, Roboz GJ
    Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
    J Clin Oncol. 2017 Jun 27:JCO2017726745. doi: 10.1200/JCO.2017.72.6745.
    PubMed     Abstract available


  160. GROMMES C, DeAngelis LM
    Primary CNS Lymphoma.
    J Clin Oncol. 2017 Jun 22:JCO2017727602. doi: 10.1200/JCO.2017.72.7602.
    PubMed     Abstract available


    May 2017
  161. STAIGER AM, Ziepert M, Horn H, Scott DW, et al
    Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    J Clin Oncol. 2017 May 19:JCO2016703660. doi: 10.1200/JCO.2016.70.3660.
    PubMed     Abstract available


  162. WITZIG TE
    Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
    J Clin Oncol. 2017 May 17:JCO2017732578. doi: 10.1200/JCO.2017.73.2578.
    PubMed    


  163. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed    


  164. LANDSBURG DJ, Falkiewicz MK, Maly J, Blum KA, et al
    Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
    J Clin Oncol. 2017 May 5:JCO2017722157. doi: 10.1200/JCO.2017.72.2157.
    PubMed     Abstract available


  165. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Abstract available


  166. LAURENT C, Baron M, Amara N, Haioun C, et al
    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol. 2017 May 1:JCO2016712083. doi: 10.1200/JCO.2016.71.2083.
    PubMed     Abstract available


    April 2017
  167. KAMDAR MK, Smith SM
    Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
    J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
    PubMed     Abstract available


  168. CHEN R, Zinzani PL, Fanale MA, Armand P, et al
    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
    J Clin Oncol. 2017 Apr 25:JCO2016721316. doi: 10.1200/JCO.2016.72.1316.
    PubMed     Abstract available


  169. THIEBLEMONT C, Tilly H, Gomes da Silva M, Casasnovas RO, et al
    Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    J Clin Oncol. 2017 Apr 20:JCO2017726984. doi: 10.1200/JCO.2017.72.6984.
    PubMed     Abstract available


  170. SASSE S, Brockelmann PJ, Goergen H, Plutschow A, et al
    Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    J Clin Oncol. 2017 Apr 18:JCO2016709410. doi: 10.1200/JCO.2016.70.9410.
    PubMed     Abstract available


  171. MEYER RM
    Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty.
    J Clin Oncol. 2017 Apr 3:JCO2017722611. doi: 10.1200/JCO.2017.72.2611.
    PubMed    


    March 2017
  172. ZUCCA E, Conconi A, Martinelli G, Bouabdallah R, et al
    Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
    J Clin Oncol. 2017 Mar 29:JCO2016706994. doi: 10.1200/JCO.2016.70.6994.
    PubMed     Abstract available


  173. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
    Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
    PubMed     Abstract available


    January 2017
  174. HERRERA AF, Mei M, Low L, Kim HT, et al
    Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    J Clin Oncol. 2017;35:24-31.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: